

Breath by breath: Journey through lung cancer.

Joran Lucas*

Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium

Introduction

Lung cancer, a formidable adversary in the realm of oncology, represents not just a physical ailment but a profound and challenging journey for individuals affected by it. Each step through this intricate landscape involves a multitude of emotions, decisions, treatments, and support systems that shape a narrative unique to each individual touched by this disease [1].

Lung cancer, characterized by the uncontrolled growth of abnormal cells in the lungs, is often linked to smoking, but it can also affect non-smokers due to various factors like genetics, environmental exposures, and lifestyle choices. Its two primary types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), present distinct challenges in terms of prognosis, treatment options, and management [2].

The journey through lung cancer begins with a tumultuous whirlwind of emotions. From shock and denial upon diagnosis to fear, anger, and anxiety about the uncertainties ahead, individuals and their loved ones experience a rollercoaster of feelings. Coping with the emotional strain while processing the gravity of the diagnosis becomes an integral part of the journey [3].

The path ahead in lung cancer treatment often involves a complex array of choices. From surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, to clinical trials, each option comes with its own set of considerations, risks, and potential outcomes. Discussions with healthcare providers become crucial in determining the most suitable course of action based on the type and stage of the cancer, as well as the individual's overall health [4].

While treatments aim to combat the cancer, they often bring along their own set of challenges. Side effects such as fatigue, nausea, hair loss, pain, and changes in appetite can profoundly impact the quality of life for individuals undergoing treatment. Managing these side effects becomes an ongoing endeavor, often requiring a delicate balance between addressing the cancer and maintaining the individual's well-being [5].

Amidst the trials and tribulations, a robust support network emerges as a vital pillar. Family, friends, support groups, counselors, and healthcare professionals provide not only emotional support but also guidance, information, and a sense of companionship throughout the journey. Their presence and understanding offer solace during the most trying times [6].

Lung cancer brings with it a unique sense of uncertainty. While some individuals may respond well to treatments and experience remission, others may face recurrent or advanced stages of the disease. Living with this uncertainty, balancing hope with acceptance, becomes a profound aspect of the journey through lung cancer.

For some individuals, particularly those with advanced stages of lung cancer, discussions about end-of-life care and palliative options become essential. Addressing these topics openly and with compassion allows individuals and their loved ones to make informed decisions about their preferences for care, comfort, and dignity in the latter stages of the journey [7].

Amidst the challenges, there's a glimmer of hope in the realm of lung cancer. Ongoing advancements in research, innovative treatments, targeted therapies, immunotherapies, and personalized medicine continue to redefine the landscape of lung cancer care. Clinical trials offer promising avenues, providing hope not just for current patients but for future generations as well [8].

As the journey progresses, individuals affected by lung cancer often find solace in leaving a legacy—whether it's through advocating for awareness, participating in support groups, or simply sharing their experiences to empower others facing similar challenges. Reflecting on the journey and finding meaning in their experiences becomes a powerful aspect of the narrative [9].

A lung cancer diagnosis initiates an emotional roller coaster for individuals and their families. Fear, uncertainty, and grief become companions on this unexpected journey. "Breath by Breath" signifies the gradual, deliberate steps taken in navigating these emotions. From the shock of the initial diagnosis to the ongoing challenges of treatment and the uncertainty of the future, individuals find solace and strength in the simple act of breathing, embracing the present moment, and taking each breath as it comes [10].

Conclusion

The journey through lung cancer is intricate, emotional, and deeply personal. It's a journey that encapsulates not just the physical battle against a formidable disease but also the resilience, hope, and strength exhibited by individuals and their support systems. Each breath taken through this journey embodies courage, determination, and the unyielding spirit to confront and navigate the complexities of lung cancer. As advancements in research and care continue, the journey

*Correspondence to: Joran Lucas, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium. E-mail: lucasjoran@un.be

Received: 06-Nov-2023, Manuscript No. AAJCRM-23-122822; Editor assigned: 09-Nov-2023, PreQC No. AAJCRM-23-122822 (PQ); Reviewed: 23-Nov-2023, QC No. AAJCRM-23-122822; Revised: 25-Nov-2023, Manuscript No. AAJCRM-23-122822 (R); Published: 31-Nov-2023, DOI: [10.35841/aaajcrm-7.6.178](https://doi.org/10.35841/aaajcrm-7.6.178)

evolves, offering newfound hope and possibilities for those affected by this disease.

References

1. Man WH, de Steenhuijsen Pijters WA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. *Nat Rev Microbiol*. 2017;15(5):259-70.
2. Ramaswamy A. Lung cancer screening: Review and 2021 update. *Curr Pulmonol Rep*. 2022;11(1):15-28.
3. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. *Nature*. 2018;553(7689):446-54.
4. Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario clinical practice guideline update. *J Clin Oncol*. 2017;35(25):2960-74.
5. Ettinger DS, Wood DE, Aggarwal C, et al. Non-small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines. *JNCCN*. 2019;17(12):1464-72.
6. CG A. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2011;29:3825-31.
7. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. *Lancet Oncol*. 2012;13(3):247-55.
8. Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin*. 2011;61(2):69-90.
9. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol*. 2016;11(1):39-51.
10. Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. *J Thorac Oncol*. 2015;10(7):990-1003.